NCT07485283 · Phase 4 · ACTIVE NOT RECRUITING
Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
This trial tests whether the Shingrix shingles vaccine lowers the chance of heart attack, stroke, cardiovascular death, and a new dementia diagnosis in adults 65 and older in Denmark. About 162,000 people will get two doses or no vaccine. It is a Phase 4 trial, meaning the vaccine is already approved for shingles and is now being studied for other effects.
Eligibility criteria
Inclusion Criteria: 1. Age 65 years and above at the time of consent 2. Self-reported ability to understand written and spoken Danish or English 3. Informed consent form has been signed and dated Exclusion Criteria: The study has the following exclusion criteria which will be assessed through self-reporting: 1. A prior diagnosis of dementia 2. Chronic inflammatory rheumatic disease and concomitant immunosuppressive therapy 3. Prior herpes zoster vaccination
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-10-14